Opticon delays launch of clinical trial:
This article was originally published in Clinica
Executive Summary
Opticon Medical has delayed a pivotal clinical trial of its urinary catheter, the Option-vf, in order to implement an "engineering change" to a feature of the device, says the company. Opticon president William Post said that the delay in patient enrolment in exchange for the latest technology is "worth the trade off". Last year, the Dublin, Ohio-based company reported promising results from a pilot study of the Option-vf, which is designed for the short-term management of urinary retention following lower urinary tract surgery (see Clinica No 923, p 17).